{"id":1693,"date":"2026-03-25T12:00:55","date_gmt":"2026-03-25T12:00:55","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/03\/25\/ms-therapy-cdr111-advances-after-meeting-preclinical-milestone\/"},"modified":"2026-03-25T12:00:55","modified_gmt":"2026-03-25T12:00:55","slug":"ms-therapy-cdr111-advances-after-meeting-preclinical-milestone","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/03\/25\/ms-therapy-cdr111-advances-after-meeting-preclinical-milestone\/","title":{"rendered":"MS therapy CDR111 advances after meeting preclinical milestone"},"content":{"rendered":"<p><a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2026\/03\/25\/ms-therapy-cdr111-advances-meeting-preclinical-milestone\/\" title=\"MS therapy CDR111 advances after meeting preclinical milestone\" rel=\"nofollow\"><img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"450\" src=\"https:\/\/multiplesclerosisnewstoday.com\/wp-content\/uploads\/2026\/03\/antibody-800x450.jpg\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"A 3d rendering shows antibodies.\" style=\"margin: auto;margin-bottom: 15px;max-width: 100%\" data-wp-pid=\"160684\" \/><\/a><\/p>\n<p>An experimental therapy designed to eliminate harmful B-cells \u2014 key drivers of inflammation in multiple sclerosis (MS) and other autoimmune diseases \u2014 has reached an early development milestone. The treatment candidate, CDR111, is being developed under a collaboration between CDR-Life and Boehringer Ingelheim. The milestone was achieved after proof-of-concept studies in cells and animal models, [&#8230;]<\/p>\n<p>The post <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2026\/03\/25\/ms-therapy-cdr111-advances-meeting-preclinical-milestone\/\">MS therapy CDR111 advances after meeting preclinical milestone<\/a> appeared first on <a href=\"https:\/\/multiplesclerosisnewstoday.com\">Multiple Sclerosis News Today<\/a>.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2026\/03\/25\/ms-therapy-cdr111-advances-meeting-preclinical-milestone\/\" rel=\"nofollow noopener\" target=\"_blank\">multiplesclerosisnewstoday.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>An experimental therapy designed to eliminate harmful B-cells \u2014 key drivers of inflammation in multiple sclerosis (MS) and other autoimmune diseases \u2014 has reached an early development milestone. The treatment candidate, CDR111, is being developed under a collaboration between CDR-Life and Boehringer Ingelheim. The milestone&hellip;<\/p>\n","protected":false},"author":0,"featured_media":1694,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-1693","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=1693"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1693\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media\/1694"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=1693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=1693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=1693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}